Appointments
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: New CEOs at RhoVac and Step Pharma
Recent appointments at executive level in pharmaceutical and biotech companies include new CEOs at RhoVac AB, Step Pharma and Ascendis Health, a new chief business officer at MaaT Pharma, and a new chief scientific officer at Pieris Pharmaceuticals.
Executives On The Move: Bayer Acquires Talent from J&J And Synlogic And Stealth Decide On Chief Positions
Former J&J exec joins Bayer AG as head, business development and licensing. Synthetic biotic medicines firm Synlogic welcomes a CMO and Stealth BioTherapeutics, which is developing candidates for treatment of mitochondrial dysfunction, adds a CFO.
Executives On The Move: Management Changes In Quality, Tech And Finance At Eisai, Frequency Therapeutics And Fresenius
Japanese pharma Eisai picks Merck Research exec as VP, Global Clinical Quality Assurance and former Moderna scientist joins regenerative med company Frequency Therapeutics in SVP, Technology Development slot. Meanwhile, Fresenius Medical Care announces CFO hire.
Executives On The Move: Exits Are In the News This Week From Bristol-Myers Squibb, Glenmark And EMD Serono
Daiichi Sankyo appoints former Bristol-Myers Squibb global head of talent as its chief people officer and Glenmark CMO switches to same position at cellular medicines firm Mesoblast Ltd. At GlaxoSmithKline, an EMD Serono SVP will be president, US Pharma.
Executives On The Move: Top Hires At Ribon And SQZ And Roche Promotes A Business Leader
Ribon Therapeutics, developer of new cancer medicines, chooses a CBO and former Merck & Co. SVP joins cellular therapies firm SQZ Biotech. Meanwhile, Roche promotes global diagnostics VP to President, Roche Diagnostics Canada.
Executives On The Move: Kite Pharma Announces Its Next CEO And A Trio Of VPs For Tilray
T-cell therapy firm Kite Pharma announces a former Eli Lilly VP as its next CEO. Over at Canadian pharma and cannabis business Tilray, three new VPs for Europe in expansion, marketing and commercial development.
Executives On The Move: EIP Pharma Acquires Talent From Shire, And Arvinas And Selvita Fill Top Medical Spots
CNS-focused therapeutics developer EIP Pharma adds former Shire VP as CFO. And new CMOs for protein-degradation therapeutics firm Arvinas and European drug discovery business Selvita.
Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More
Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.
Executives On The Move: Amgen Biologics Head Joins Immusoft; Julphar Poaches From Novartis, AbbVie And Mylan
Executives On The Move: Exits At AbbVie And Shire Pharma, And A Regional Leadership Appointment At Acino
AbbVie medical exec now holds CMO position at vaccines company Vaccitech, and Shire Pharma head of international commercial picked for CEO of protein-misfolding firm Orphazyme. Swiss pharma Acino International appoints former Novartis services head as General Manager, Latin America.
Asia Executives On The Move: Changes At Pfizer, Lilly, Alexion, Healios
The coming of summer has brought a flurry of executive changes in the Asia-Pacific health sector. Pfizer China's head of R&D is leaving while Lilly and Alexion in Japan have new presidents.
Executives On The Move: Alnylam Decides On Next CFO, Annexon Picks A CBO And Eli Lilly Announces A New Area President
At Alnylam a new CFO is in place. Annexon Biosciences chooses as CBO a Johnson & Johnson Innovation leader and Eli Lilly & Co promotes exec to SVP and President, Lilly Bio-Medicines.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.